Hormonal
Increased body weight and mechanical loading via the mechanostat increase bone mass and reduce osteoporosis prevalence, but this benefit plateaus or reverses at morbid obesity levels due to compromised bone quality and altered fracture mechanics.
Maintaining a healthy body weight is crucial for bone health because mechanical loading stimulates bone formation. However, extreme obesity may not provide additional bone benefits and can compromise bone quality. Focus on preserving lean muscle mass and engaging in weight-bearing activities rather than simply pursuing weight loss if your bone density is low.
Weight-dependent loading of the skeleton plays an important role in establishing and maintaining bone mass and strength... At the limits, extreme deviations from normal weight and body composition are associated with impaired optimization of bone strength to prevailing body size.
Why this rating
Based on a comprehensive review of human observational studies, animal models, and spaceflight data.
Source
Influence of body weight on bone mass, architecture and turnover
Urszula T. Iwaniec et al. · Journal of Endocrinology · 2016
DOI 10.1530/joe-16-0089
More from this paper
- Weightlessness and reduced mechanical loading (e.g., spaceflight, bed rest) cause rapid, site-specific bone loss, particularly in weight-bearing bones, with recovery being significantly slower than the rate of loss.Strong
- Leptin and estrogen signaling modulate the skeleton's sensitivity to mechanical loading, with leptin deficiency requiring higher body weight to achieve equivalent bone mass.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →